I Know First Review: May 25th, 2016

I Know First Review

The stocks selected here are the top performing stocks from I Know First: Biotech Stock  Forecast for the last three 3 Months  found in the article titled “Biotech Stocks To Watch ” This forecast is part of the Biotech  Stocks package, as one of I Know First’s quantitative investment solutions. The I Know First Average return for the long position was 38.16% over the 3 Months time period outperforming the S&P 500’s 8.06% return by a wide margin.

I Know First Review


Learn how to read the predictions: Instructions

Learn how to strategize with the forecast: Algorithmic Trading Strategies

Please, note-for trading decisions use the most recent forecast.


I Know First ReviewSignal : 18.29

Predictability : 0.37

Return : 15.99%


Heron Therapeutics is a pharmaceutical company focused on the development and commercialization of innovative medical treatments utilizing its proprietary polymer. The principal mission of the company is to improve the lives of the patient by developing best in classes medicines that address unmet medical needs. By applying an innovative science and technologies to therapeutic agents with well-known pharmacology, the company aims to develop patient-focused solutions that potentially. On may 5th , Heron Therapeutics announces First Quarter 2016 financial results and recent corporate progress.


I Know First ReviewSignal : 13.93

Predictability : 0.45

Return : 23.44%


Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. On may 16th , in Israel ,Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded, PLX-PAD, cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD).


alexion logoSignal : 11.83

Predictability : 0.46

Return : 3.25%


Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they suffer and their families suffer too having little hope. On may 11 , 2016 , Alexion pharmaceuticals helds its annual meeting of Shareholders in New Heaven , in Connecticut.


ARIAD LOGOSignal : 9.49

Predictability : 0.29

Return : 64.33%


ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. On may 24th , ARIAD Pharmaceutical announced the appointment of Jennifer L.Herron as executive vice president, chief commercial officer May 31 2016. She will report to ARIAD’s president and chief executive officer.


KERYX LOGOSignal : 8.44

Predictability : 0.52

Return : 78.55%


Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Investors in Keryx Biopharmaceutical , a small-cap drug maker primarly focused on creating products that threat renal disease , had a prosperous company’s stock soared more than 18% higher during the month , according to data from S&P Global Market Intelligence.


Medivation logoSignal : 7.60 

Predictability :  0.33

Return : 96.91%


Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. France’s Sanofi SA is preparing to name candidates it will put forward to replace the entire board of US cancer drug company as early as wednesday accordind to people familiar with the matter.



Signal : 7.44

Predictability : 0.31

Return : 32.69%


Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. On may 19th , Achillion Pharmaceuticals announced the upcoming of an e-poster summarizing a late breaking abstract accepted for the 21st Congress of the European Hematology Association.



Predictability : 0.26

Return : 12.86%


Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. On may 23th , Incyte was the biggest gainer among the large-cap stocks of the shares nasdaq Biotechnology with a gain of 3.9%. In this presentation at the UBS , Global Healthcare conference , Incyte managment told investors that it now expects the revenue from jakafi sales for 2016 to be in the range of $815 million-830 million


Novo nordisk

Signal :5.56

Predictability : 0.37

Return : 7.73%


Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. In London , On may 25 , European Shares climbed to a new four week high on wednesday with Novo Nordisk leading in the market higher after a U.S advisory panel recommended approval of its new diabete drugs.


anipharmaceutical logoSignal : 5.42

Predictability : 0.32

Return : 45.91%


ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. The company focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. On may 23th , ANI pharmaceuticals announced the appointment of Mark Ginski as Vice President Corticotropin product development.